Fig. 7From: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trialPharmacodynamics by dose cohorts on Cycle 1 (A) and on Day 1 of Cycle 1 (B)Back to article page